📊 LYEL Key Takeaways
Is LYEL a Good Investment? Thesis Analysis
Lyell Immunopharma is a pre-revenue stage biopharmaceutical company with severe cash burn and no clear path to profitability. The company is consuming approximately $150M in annual operating cash flow while generating minimal revenue ($36K), indicating an unsustainable business model with high execution risk and significant dilution risk.
Why Buy LYEL? Key Strengths
- Strong liquidity position with $60.2M in cash and 5.28x current ratio provides runway for operations
- Moderate leverage with 0.00x debt-to-equity ratio reduces balance sheet risk
- Substantial asset base of $340.1M with positive stockholders equity of $248.2M
LYEL Investment Risks to Consider
- Extreme cash burn of $150M annually with only $60.2M cash remaining indicates 3-4 month runway without additional financing
- Revenue of $36K with -41% YoY decline confirms company has no commercial traction or approved products generating sales
- Operating losses of $269.4M and negative operating margin of -748344% reflect pre-clinical/early-stage development phase with massive R&D expenses and zero revenue offsetting
- Negative free cash flow of $150.8M annually requires continuous capital raises, exposing shareholders to severe dilution
- 13 insider Form 4 filings in 90 days may indicate stock sales or option exercises, potentially signaling insider concerns
Key Metrics to Watch
- Cash burn rate and runway to profitability or next financing event
- Clinical trial progress and regulatory milestones for pipeline programs
- R&D spending efficiency and allocation across pipeline candidates
- Gross cash position and frequency of dilutive capital raises
- Insider transaction patterns and insider confidence signals
LYEL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.28x current ratio provides a solid financial cushion.
LYEL Profitability Ratios
LYEL vs Healthcare Sector
How Lyell Immunopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LYEL Overvalued or Undervalued?
Based on fundamental analysis, Lyell Immunopharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LYEL Balance Sheet & Liquidity
LYEL 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Lyell Immunopharma, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-18.70 indicates the company is currently unprofitable.
LYEL Growth Metrics (YoY)
LYEL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $15.0K | -$38.8M | $-2.13 |
| Q2 2025 | $8.0K | -$42.7M | $-2.89 |
| Q1 2025 | $3.0K | -$52.2M | $-0.18 |
| Q3 2024 | $25.0K | -$44.6M | $-0.17 |
| Q2 2024 | $13.0K | -$45.8M | $-0.18 |
| Q1 2024 | $3.0K | -$60.7M | $-0.24 |
| Q3 2023 | $3.0K | -$50.9M | $-0.20 |
| Q2 2023 | $27.0K | -$36.3M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LYEL Capital Allocation
LYEL SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Lyell Immunopharma, Inc. (CIK: 0001806952)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LYEL
What is the AI rating for LYEL?
Lyell Immunopharma, Inc. (LYEL) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LYEL's key strengths?
Claude: Strong liquidity position with $60.2M in cash and 5.28x current ratio provides runway for operations. Moderate leverage with 0.00x debt-to-equity ratio reduces balance sheet risk.
What are the risks of investing in LYEL?
Claude: Extreme cash burn of $150M annually with only $60.2M cash remaining indicates 3-4 month runway without additional financing. Revenue of $36K with -41% YoY decline confirms company has no commercial traction or approved products generating sales.
What is LYEL's revenue and growth?
Lyell Immunopharma, Inc. reported revenue of $36.0K.
Does LYEL pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
Where can I find LYEL SEC filings?
Official SEC filings for Lyell Immunopharma, Inc. (CIK: 0001806952) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LYEL's EPS?
Lyell Immunopharma, Inc. has a diluted EPS of $-16.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LYEL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lyell Immunopharma, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LYEL stock overvalued or undervalued?
Valuation metrics for LYEL: ROE of -110.6% (sector avg: 15%), net margin of -762,355.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LYEL stock in 2026?
Our dual AI analysis gives Lyell Immunopharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LYEL's free cash flow?
Lyell Immunopharma, Inc.'s operating cash flow is $-150.0M, with capital expenditures of $780.0K. FCF margin is -418,900.0%.
How does LYEL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -762,355.6% (avg: 12%), ROE -110.6% (avg: 15%), current ratio 5.28 (avg: 2).